Keyword: Audentes Therapeutics
Parker Institute-backed biotech Xyphos has been bought out by Japanese pharma Astellas as it looks to bolster its cancer pipeline.
The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is nearing approval.
Audentes Therapeutics has hired Sangamo CMO Ed Conner to fill one of two vacancies created by the back-to-back departures of members of its C-suite.
Gene therapy player Audentes Therapeutics priced at the midpoint of its IPO range, raising $75 million, and then proceeded to move up about 10% in early trading on July 20.